Crystal engineering of pharmaceutical co-crystals from polymorphic active pharmaceutical ingredients.
The carboxylic acid-primary amide supramolecular heterosynthon is exploited for the generation of pharmaceutical co-crystals that contain two active pharmaceutical ingredients that are polymorphic in their pure forms.